SCHEMBL6813402

SCHEMBL6813402

COc1ccc(NC(=O)c2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.77
CYP3A4 P08684 1/20 0.77
TSHR P16473 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
KMT2A Q03164 9/20 0.75
MEN1 O00255 8/20 0.75
MAPT P10636 6/20 0.75
POLB P06746 4/20 0.72
RAB9A P51151 2/20 0.65
NPC1 O15118 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HTT P42858 1/20 0.64
LMNA P02545 1/20 0.63
SETD7 Q8WTS6 1/20 0.62
ALOX5 P09917 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.59
GAA P10253 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16129682 0.93 ALDH1A1 (0.74) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL4189026 0.87 POLB (0.78) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL19034437 0.87 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL9235485 0.86 ALDH1A1 (0.57) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL11195939 0.86 KMT2A (0.61) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL6809707 0.85 ALDH1A1 (0.70) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL16098533 0.85 ALDH1A1 (0.86) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL14383794 0.85 ALDH1A1 (0.73) ALDH1A1CYP3A4TSHRTDP1KMT2A
SCHEMBL1663896 0.83 MEN1 (0.65) TDP1KMT2AMEN1MAPTPOLB
SCHEMBL11957605 0.83 ALDH1A1 (0.55) ALDH1A1CYP3A4TSHRTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed
EP-1042276-B1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER LAMBERT CO (US) 2004-11-17 EP disclosed
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US disclosed
US-6268387-B1 INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. WARNER-LAMBERT COMPANY 2001-07-31 US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 EP disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS ALDH1A1 369/4885CYP3A4 933/4885TSHR 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.